Pharvaris has reported positive Phase 3 CHAPTER-3 results for deucrictibant extended-release, with the once-daily oral bradykinin B2 receptor antagonist reducing the mean monthly hereditary angioedema attack rate by 83% versus placebo across patients with three forms of the disease. The Nasdaq-listed biotechnology developer plans to use the study in regulatory applications beginning in the first half of 2027, potentially creating an oral prevention franchise alongside its immediate-release deucrictibant formulation already being developed for on-demand attack treatment.
The strategic attraction is easy to see. Hereditary angioedema management has become substantially more effective, but long-term prophylaxis still requires patients and clinicians to balance efficacy, administration burden and breakthrough-attack planning. Pharvaris is attempting to collapse part of that complexity into a single molecular franchise, using one formulation for prevention and another for rapid oral treatment when attacks occur.
CHAPTER-3 also arrives with an efficacy magnitude capable of supporting that ambition. Among participants with Type 1 or Type 2 hereditary angioedema, the mean monthly attack rate was 87% lower with deucrictibant XR than with placebo. The result does not establish superiority over approved injectable or oral competitors because CHAPTER-3 was not a head-to-head trial, but it gives Pharvaris considerably more credibility when arguing that oral convenience does not necessarily require a large sacrifice in disease control.
Why does CHAPTER-3 matter beyond simply meeting another hereditary angioedema endpoint?
CHAPTER-3 randomized 85 adolescents and adults from 21 countries in a two-to-one ratio to receive deucrictibant XR 40 mg once daily or placebo for 24 weeks. The trial included HAE Type 1, Type 2 and hereditary angioedema with normal C1 inhibitor, making the population broader than the traditional C1 inhibitor-deficient groups that dominate many registrational programs. Pharvaris reported that the primary endpoint and all sequentially tested secondary efficacy endpoints achieved statistical significance.
The inclusion of HAE with normal C1 inhibitor is particularly interesting because that group can be more diagnostically heterogeneous. Type 1 and Type 2 HAE have well-established relationships with C1 inhibitor deficiency or dysfunction, whereas normal-C1-inhibitor disease encompasses less uniform biological pathways and can be harder to characterize. Evidence across that broader population may therefore become important if regulators accept a correspondingly broad label.
The strongest numerical result emerged in the 80 patients with Type 1 or Type 2 disease, where the attack-rate reduction reached 87%. That subgroup result provides reassurance that the overall 83% reduction was not being driven by an unusual response in the smaller normal-C1-inhibitor cohort. Full presentation of subgroup sizes, baseline attack frequencies and confidence intervals will still be needed before the breadth of efficacy can be judged properly.
The trial also showed early protection during the first week and sustained benefit across 24 weeks, which is relevant for a prophylactic medicine. A drug that requires an extended loading period may leave patients exposed during initiation, while a therapy that loses effectiveness between doses creates another problem. The topline description suggests neither pattern dominated CHAPTER-3, although detailed pharmacodynamic and individual attack-rate data remain necessary.
Can deucrictibant really deliver injectable-like efficacy without an injectable treatment burden?
The commercial proposition rests on oral administration. Preventive HAE therapies already include highly effective injectable approaches, and the competitive question is therefore not whether an oral tablet sounds more convenient but whether convenience can be delivered without accepting materially worse disease control. An 83% placebo-adjusted attack-rate reduction gives Pharvaris a strong starting point in that debate.
Cross-trial comparisons require considerable caution. Different HAE studies enroll patients with different baseline attack rates, use varying run-in periods and can differ in rescue-treatment rules and endpoint methodology. Saying that deucrictibant has matched a specific competing drug would therefore go beyond what CHAPTER-3 proves.
What the data do show is that oral B2 receptor antagonism can produce a large prophylactic effect in a pivotal randomized study. That finding is important because bradykinin is the downstream mediator responsible for the vascular permeability that causes swelling in HAE. Blocking the B2 receptor directly offers a mechanism that acts close to the clinical consequence of excessive bradykinin signaling rather than attempting to modify several upstream components of the kallikrein-kinin pathway.
The extended-release formulation is engineered to maintain sufficient exposure across a full day, while Pharvaris’ immediate-release capsule is designed to act rapidly during an acute attack. If both are approved, the same active molecule could occupy both sides of HAE management. That would create a distinctive franchise architecture, although payers may still evaluate the prophylactic and rescue products separately.
Why does having both immediate-release and extended-release deucrictibant change the commercial equation?
Pharvaris is already advancing deucrictibant immediate-release for on-demand therapy following the positive RAPIDe-3 program. In that study, the immediate-release formulation delivered a median time to onset of symptom relief of 1.28 hours and supported regulatory submissions for acute HAE treatment. The prevention program now gives Pharvaris the possibility of offering a patient a daily tablet and an oral rescue medicine built around the same target.
That creates potential advantages in physician familiarity and patient education. Specialists who become comfortable with deucrictibant’s pharmacology in acute treatment may be more willing to consider the extended-release formulation for prevention, while the manufacturer can build one commercial organization around a connected disease-management strategy. Manufacturing and supply infrastructure may also share elements even though the formulations and dosing objectives differ.
The model is not automatically commercially efficient. Patients who achieve excellent control on daily prophylaxis may still carry a different approved rescue medication, particularly if clinicians prefer mechanistic or formulation diversity for breakthrough attacks. Payers may also favor established therapies through rebates and formulary contracts, meaning a scientifically coherent franchise can still encounter fragmented reimbursement.
Pharvaris must also demonstrate that long-term safety remains favorable when the drug shifts from episodic use to continuous exposure. A medicine taken only during attacks creates a very different cumulative exposure profile from a tablet taken every day for years. CHAPTER-4, the ongoing open-label extension, will therefore matter for the eventual confidence of both regulators and prescribers.
What safety questions remain after a largely favorable 24-week Phase 3 profile?
Pharvaris reported that most treatment-emergent adverse events were mild or moderate and that no treatment-related serious adverse events occurred in CHAPTER-3. One participant in each study group discontinued treatment because of an adverse event, suggesting there was no obvious imbalance in discontinuation at the topline level. Those are reassuring signals, but they are not a substitute for the full adverse-event table.
Investors and clinicians will pay particular attention to liver laboratory findings and other potential class or molecule-specific safety concerns once detailed results are presented. With a chronic prophylactic therapy, even relatively uncommon laboratory abnormalities can become meaningful because patients may remain exposed for years. Regulators will also consider the combined safety database across the immediate-release and extended-release programs rather than treating them as entirely separate molecular entities.
Cardiovascular safety has also been an area of interest in the broader deucrictibant program because bradykinin signaling intersects with vascular physiology. Pharvaris has previously presented analyses intended to support a favorable cardiovascular profile, but larger cumulative exposure will provide a stronger test. The fact that CHAPTER-3 did not reveal an obvious serious safety imbalance is encouraging without closing the question.
Post-approval competitiveness, if approval is eventually granted, will depend on the balance between efficacy, tolerability and monitoring requirements. A once-daily oral medicine loses some of its convenience advantage if it requires burdensome laboratory surveillance or complicated drug-interaction management. The final prescribing information could therefore influence positioning nearly as much as the headline attack-rate reduction.
Why did Pharvaris shares jump after the data despite an already competitive HAE market?
Pharvaris shares rose sharply following the announcement, including a double-digit early trading move, because CHAPTER-3 removed one of the most important clinical risks in the company’s pipeline. Before the readout, investors knew that the immediate-release formulation had produced positive acute-treatment data, but prophylaxis represented a separate and commercially substantial opportunity. The 83% attack reduction gives that second program a pivotal efficacy foundation.
The market reaction also reflects the economics of rare disease. HAE is a relatively small population compared with common chronic disorders, but treatment intensity and long-term use support substantial per-patient commercial value. A successful product does not need millions of users to become important to a biotechnology company the size of Pharvaris.
Competition remains formidable. Established HAE manufacturers have strong relationships with specialist centers, patient organizations and payers, while several therapies already provide excellent prevention. An oral entrant must therefore win not merely by being new, but by persuading patients and physicians that its efficacy, convenience and safety justify switching from a regimen that may already be working.
Pharvaris has strengthened its financial position ahead of that contest. The biotechnology developer reported €318 million in cash and equivalents at the end of June and completed a $132.3 million underwritten equity offering earlier in 2026, extending its expected cash runway into 2028. That provides resources for regulatory work and commercial preparation, although launching two formulations would still require disciplined spending.
What has to happen before deucrictibant becomes a two-product HAE franchise?
The immediate-release and extended-release programs now have different regulatory clocks. The immediate-release NDA is already under FDA review with an April 23, 2027 PDUFA date, while the extended-release prophylaxis submission is planned for the first half of 2027. If both reviews progress successfully, Pharvaris could move from clinical-stage developer to multi-product commercial rare-disease company in a relatively compressed period.
That transition introduces operational risk. Building medical affairs, market access, patient services, specialty distribution and field commercial infrastructure for one rare-disease launch is challenging; preparing overlapping launches increases the complexity. The common molecule and therapeutic community provide efficiencies, but the company still has to execute across two indications and dosing contexts.
Detailed CHAPTER-3 presentation will be the next evidence milestone. Investors will want absolute attack rates, attack-free proportions, quality-of-life measures, subgroup results and a complete safety profile rather than only percentage reductions. Regulators will examine whether the trial supports the breadth of the proposed label, particularly the normal-C1-inhibitor population.
The topline result nevertheless changes the strategic position materially. Pharvaris no longer has to argue mainly from Phase 2 prophylaxis data or from the success of its rescue formulation. It now has a successful pivotal prevention trial showing that once-daily oral B2 receptor blockade can produce a large reduction in HAE attacks. The remaining question is whether that efficacy can survive regulatory scrutiny and then persuade patients already served by highly effective competitors to change how they manage a lifelong disease.
